title: Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma.
abstract: The aim of the present study was to retrospectively evaluate whether a high-dose sequential chemotherapy programme (HDS: cyclophosphamide, methotrexate, etoposide) administered prior to autologous transplantation could optimize the salvage of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma. Between 1985 and 1999, 103 patients (median age 43 years, range 16-65) from eight Italian centres and one Swiss centre, with refractory (n = 38) or relapsed (n = 65) diffuse large B-cell and T-cell lymphoma, were treated using HDS followed by high-dose regimens with autologous haematopoietic stem cell transplantation. Eighty-three patients responded to the HDS regimen (81%, 95% C.I., 73- 88%) and 79 eventually achieved a complete response (CR) after autotransplantation (90%, 95% C.I., 81- 96%). None of 20 cases resistant to HDS attained CR. Treatment-related mortality was 4%. After a median follow-up of 24 months (range 6-174 months), 3-year estimates of overall survival, event-free survival and disease-free survival were 47% (95% C.I., 36-59%), 44% (95% C.I., 34-54%) and 64% (95% C.I., 50-74%) respectively. Multivariate analysis showed that chemosensitivity to HDS represented the strongest predictor of both CR and survival. This retrospective study shows that salvage treatment using HDS had relatively low toxicity and was associated with remarkable response rates, allowing further effective therapy with high-dose autograft programmes.
authors.affiliation: Divisione di Ematologia, Ospedali Riuniti di Bergamo, Bergamo, Italy. oro@ospedaliriuniti.bergamo.it
authors.forename: S
authors.initials: S
authors.lastname: Cortelazzo
authors.forename: A
authors.initials: A
authors.lastname: Rambaldi
authors.forename: A
authors.initials: A
authors.lastname: Rossi
authors.forename: E
authors.initials: E
authors.lastname: Oldani
authors.forename: M
authors.initials: M
authors.lastname: Ghielmini
authors.forename: F
authors.initials: F
authors.lastname: Benedetti
authors.forename: C
authors.initials: C
authors.lastname: Tarella
authors.forename: F
authors.initials: F
authors.lastname: Zaglio
authors.forename: U
authors.initials: U
authors.lastname: Vitolo
authors.forename: M
authors.initials: M
authors.lastname: Di Nicola
authors.forename: E
authors.initials: E
authors.lastname: Pogliani
authors.forename: F
authors.initials: F
authors.lastname: Cavalli
authors.forename: A M
authors.initials: AM
authors.lastname: Gianni
authors.forename: T
authors.initials: T
authors.lastname: Barbui
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D012008:Recurrence; D012044:Regression Analysis; D012189:Retrospective Studies; D016879:Salvage Therapy / Q000379:methods*; D015996:Survival Rate; D014182:Transplantation, Autologous
chemical_list: D005047:Etoposide; D003520:Cyclophosphamide; D008727:Methotrexate